Adaptive Biotechnologies

Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. It harnesses the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson in September 2009 and is headquartered in Seattle, WA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Adaptive Biotechnologies reports robust Q4 performance and eyes growth opportunities

Adaptive Biotechnologies delivered strong financial performance in Q4 2022 and full-year 2022, driven by growth in MRD and immune medicine segments, showcasing operational efficiency and revenue expansion.
While facing challenges such as paused T-Detect commercialization and revenue phasing complexities, the company is well-positioned to capitalize on opportunities like market acceptance of MRD and drug discovery partnerships.
With a positive revenue outlook for 2023, supported by strategic initiatives and a strong cash position, Adaptive Biotechnologies is poised for continued growth and market leadership in the biotechnology sector.

Adaptive Biotechnologies reports robust Q1 revenue and growth prospects

Adaptive Biotechnologies showcased strong revenue growth and operational improvements in Q1 2023.
The company is strategically positioned to capitalize on opportunities in MRD business and immune medicine segment.
Challenges include potential impacts from regulatory changes and the need for milestone achievements.
Overall, Adaptive Biotechnologies remains focused on growth, innovation, and expanding its market presence.

Adaptive Biotechnologies reports revenue growth and strategic partnerships in Q2

Adaptive Biotechnologies demonstrated solid revenue growth and margin improvement in Q2 2023, with a strategic outlook for future profitability.
Strong partnerships with Genentech and advocacy for MRD as a clinical endpoint position the company for continued success in the market.
Ongoing challenges in pricing and integration efforts are being addressed, while opportunities in drug discovery and AI-driven target discovery offer growth potential.

Adaptive Biotechnologies reports Q3 revenue growth amidst industry challenges

Adaptive Biotechnologies saw mixed performance with MRD growth and Immune Medicine decline.
Company's focus on MRD profitability and novel target identification shows strategic strength.
Facing challenges from industry softening and cost pressures but eyeing revenue growth opportunities.
Maintaining long-term target of $1,600 in 2027 while making progress towards profitability.

Adaptive Biotechnologies reports mixed Q4 results, focuses on MRD growth

Adaptive Biotechnologies navigated a transformative year in 2023, with a strong focus on MRD and Immune Medicine businesses. The company faces challenges in Immune Medicine revenue decline and achieving profitability. Strategic initiatives and partnerships position the company for growth and innovation in the biotechnology sector.

Adaptive Biotechnologies posts solid Q1 results, eyes breakeven targets

Adaptive Biotechnologies reported strong MRD revenue growth and aims to reduce operating expenses significantly in 2024. Despite a net loss, the company updated full-year guidance with a focus on achieving breakeven targets by 2025 and 2026. Opportunities lie in MRD segment expansion and immune medicine development.

Adaptive Biotechnologies excels in Q3 2024, eyes growth opportunities

Adaptive Biotechnologies delivered a robust performance in Q3 2024, marked by revenue growth, cost efficiencies, and strategic advancements in key segments.
While facing challenges in maintaining growth and profitability, the company's focus on operational excellence and innovation positions it well for future success.
With upcoming product launches and continued R&D efforts, Adaptive Biotechnologies is poised to capitalize on opportunities for market expansion and margin improvement.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson on September 8, 2009 and is headquartered in Seattle, WA.

Viking Global leader Andreas Halvorsen (Trades, Portfolio) disclosed last week he trimmed the firm’s Adaptive Biotechnologies Corp.

Andreas Halvorsen Trims Adaptive Biotechnologies Stake

Microsoft

The two companies hope to decode the human immune system.

Why Is Microsoft Investing in Adaptive Biotechnologies?

The genetic diagnostics company announced the pricing of a common stock offering that suggests there's solid demand for shares.

Here's Why Adaptive Biotechnologies Is Soaring Today

SEATTLE, Jan.  23, 2020  (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced today the pricing of its underwritten public offering of 8,000,000 shares of its common stock by certain selling shareholders at a public offering price of $26.50 per share, before underwriting discounts and commissions. In addition, the selling shareholders have granted the underwriters a 30-day option to purchase up to an additional 1,200,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. Adaptive will not receive any proceeds from the sale of the shares of common stock by the selling shareholders. The offering is expected to close on January 28, 2020, subject to customary closing conditions.

Adaptive Announces Pricing of Public Offering of Common Stock

Seattle-based Adaptive Biotechnologies plans to sell up to 9.

Adaptive Biotechnologies plans to sell up to 9.2M shares; revenue grew 52% in 2019

SEATTLE, Jan.  21, 2020  (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced today the commencement of a proposed underwritten public offering of 8,000,000 shares of its common stock by certain selling shareholders. In addition, certain selling shareholders expect to grant the underwriters a 30-day option to purchase up to an additional 1,200,000 shares of its common stock in the offering. Adaptive will not receive any of the proceeds from the sale of the shares of its common stock being offered by the selling shareholders. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Adaptive Announces Proposed Public Offering of Common Stock

SEATTLE, Jan.  21, 2020  (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced today preliminary unaudited revenue for the full year 2019.

Adaptive Announces Preliminary Unaudited Revenue for Full Year 2019

SEATTLE, Jan.  13, 2020  (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced a multi-year, global diagnostic agreement with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) to utilize Adaptive’s next-generation sequencing (NGS)-based clonoSEQ® Assay to assess minimal residual disease (MRD) status in response to venetoclax in the registrational Phase III CRISTALLO (CO41685) study for the treatment of newly diagnosed people with chronic lymphocytic leukemia (CLL) plus additional future venetoclax studies in CLL. Adaptive and Genentech will partner to incorporate the clonoSEQ Assay to measure MRD status as a primary endpoint in this registrational study. Under the terms of the agreement, Adaptive will receive upfront and sample testing payments to advance the development and potential expedited approval of venetoclax in this setting.

Adaptive and Genentech Partner to Use clonoSEQ® Assay to Measure Minimal Residual Disease as a Primary Endpoint in Phase III Study of Chronic Lymphocytic Leukemia Patients

SEATTLE, Jan.  08, 2020  (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses diagnostic technologies through its MolDX program, has expanded coverage of the clonoSEQ Assay to include monitoring minimal residual disease (MRD) in Medicare patients with chronic lymphocytic leukemia (CLL). This adds to existing Medicare coverage in B-cell acute lymphoblastic leukemia (ALL) and multiple myeloma, which was established in January 2019. Medicare coverage for clonoSEQ is aligned with clinical practice guidelines in covered disease states which support assessing MRD at multiple time points throughout therapy to monitor treatment response and help predict patient outcomes. This expanded coverage policy is effective immediately and continues the positive momentum for clonoSEQ with over 175M lives covered to date.

Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Monitoring MRD in Patients With Chronic Lymphocytic Leukemia

As of late, it has definitely been a great time to be an investor Adaptive Biotechnologies.

Adaptive Biotechnologies Shares March Higher, Can It Continue?

Adaptive Biotechnologies Corp (ADPT) CEO Chad Robins on Q3 2019 Results - Earnings Call Transcript

Adaptive Biotechnologies‘ stock rose 6 percent to $30 per share in after-hours trading on Tuesday after the company reported higher revenues and narrower losses than expected for its third-quarter earnings.

Adaptive Biotechnologies beats estimates with Q3 revenue of $26.1M as shares rise 6%

A novel effort from Microsoft and Adaptive Biotechnologies to diagnose multiple diseases from a single blood test is a data challenge on the scale of Google search.

Universal blood test from Microsoft and Adaptive is a Google-sized data challenge

Guardant Health Inc

Personalis Inc

Is Wall Street's initial excitement giving way to more realistic expectations?

Here's Why Liquid Biopsy Stocks Fell as Much as 39.2% in September

Illumina

Adaptive Biotechnologies signed a deal with Illumina, the largest genetic sequencing firm in the U.

Adaptive and Illumina to make immune sequencing kits for labs, streamlining the detection of disease

Partnership Will Enable Physicians to Order Clinical Immunodiagnostic Testing that Can Be Performed in Local Laboratories Partnership Will Enable Physicians to Order Clinical Immunodiagnostic Testing that Can Be Performed in Local Laboratories

Adaptive Biotechnologies Enters Partnership with Illumina to Develop Distributable IVD Test Kits for clonoSEQ and immunoSEQ Dx

Amgen

Global partnership spans Amgen’s entire portfolio of pipeline and marketed blood cancer therapies Global partnership spans Amgen’s entire portfolio of pipeline and marketed blood cancer therapies

Adaptive Biotechnologies Enters Partnership for Use Of clonoSEQ® as Preferred MRD Test for Drug Development Across Amgen’s Hematology Franchise

The diagnostic company reported second-quarter 2019 operating results, but shares tumbled in early September.

Here's Why Adaptive Biotechnologies Rose 31.9% in August

Boeing

BridgeBio Pharma Inc

Monster Beverage

Uber

Viking Global’s top buys include 3 IPOs.

Andreas Halvorsen’s Top 5 Buys of the 2nd Quarter

Shares of Adaptive Biotechnologies Corp. ADPT, +2.55% fell 8.5% in premarket trade Wednesday after the company reported earnings that fell short of analysts' expectations and predicted lower-than-expected full-year revenue.

Adaptive Biotechnologies stock down 8.5% in premarket trade

Adaptive Biotechnologies Corp (ADPT) CEO Chad Robins on Q2 2019 Results - Earnings Call Transcript

Adaptive Biotechnologies‘ stock fell 7 percent Tuesday after the company posted larger-than-expected losses during the first quarterly earnings report since it went public in June.

Adaptive Biotechnologies shares drop as loss widens in first quarterly earnings since IPO

Adaptive Biotechnologies shares fell by more than 7% in after-hours trading Tuesday after the biotech company posted a wider-than-expected loss in its first earnings report since going public.

Adaptive Biotechnologies stock tumbles after first earnings report since IPO

Adaptive Biotechnologies Corp. ADPT, +2.55% shares were down fractionally in the extended session Tuesday after the biotech company reported a narrower-than-expected loss.

Adaptive Biotech loss narrower than expected on first post IPO report

Adaptive Biotechnologies is charting a massive expansion of its Seattle headquarters following the completion of a recent initial public offering in which the company raised $300 million.

News for Adaptive Biotechnologies Stock (ADPT)